Last Updated: November 9, 2026

Claims for Patent: RE49647

« Back to Dashboard


Summary for Patent: RE49647
Title:Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Abstract:Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
Inventor(s):Darshan Parikh, Anil Menon
Assignee: Celgene Corp
Application Number:US17/030,272
Patent Claims: 1. An oral dosage form in the form of a capsule which comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount of about 0.1 to about 3 weight percent of the total weight of the dosage form; 2) a carrier or excipient at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose; and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1; and 3) a lubricant at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

2. The oral dosage form of claim 1, wherein Compound A is present at an amount of about 0.1 to about 1 weight percent of total weight of the dosage form.

3. The oral dosage form of claim 1, wherein the carrier or excipient is present at an amount of about 95 to about 99.9 weight percent of total weight of the dosage form.

4. The oral dosage form of claim 1, wherein the starch is pregelatinized starch.

5. The oral dosage form of claim 1, wherein the lactose is anhydrous lactose.

6. The oral dosage form of claim 1, wherein the lubricant is presented present at an amount of 0.1 to 1 weight percent of total weight of the oral dosage form.

7. The oral dosage form of claim 6, wherein the lubricant is present at an amount of 0.1 to 0.5 weight percent of total weight of the dosage form.

8. An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.3 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose, and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1; and 3) a lubricant, at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

9. The dosage form of claim 8, wherein the starch is pregelatinized starch.

10. The dosage form of claim 9, wherein the pregelatinized starch is present at an amount of about 18.075 mg.

11. The dosage form of claim 8, wherein the stearic acid is present at an amount of about 0.225 mg.

12. The dosage form of claim 8, wherein the lactose is anhydrous lactose.

13. The dosage form of claim 12, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.

14. The dosage form of claim 8, which is in the form of a standard size 4 or larger capsule.

15. An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.1 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose, and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1; and 3) a lubricant, at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

16. The dosage form of claim 15, wherein the starch is pregelatinized starch.

17. The dosage form of claim 16, wherein the pregelatinized starch is present at an amount of about 18.75 mg.

18. The dosage form of claim 15, wherein the stearic acid is present at an amount of about 0.225 mg.

19. The dosage form of claim 15, wherein the lactose is anhydrous lactose.

20. The dosage form of claim 19, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.

21. The dosage form of claim 15, which is in the form of a standard size 4 or larger capsule.

22. An oral dosage form which weighs about 150 mg and comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.2 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose, and wherein the weight ratio of lactose to starch in the oral dosage form from 2.1:1 to 3.9:1; and 3) a lubricant, at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

23. The dosage form of claim 22, wherein the starch is pregelatinized starch.

24. The dosage form of claim 23, wherein the pregelatinized starch is present at an amount of about 37.5 mg.

25. The dosage form of claim 22, wherein the stearic acid is present at an amount of about 0.45 mg.

26. The dosage form of claim 22, wherein the lactose is anhydrous lactose.

27. The dosage form of claim 26, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 150 mg.

28. The dosage form of claim 22, which is in the form of a standard size 3 or larger capsule.

29. An oral dosage form which weighs about 125 mg and comprises: 1) Compound A of the following structure: or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.5 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, at an amount of about 90 to about 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose; and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1; and 3) a lubricant, at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

30. The dosage form of claim 29, wherein the starch is pregelatinized starch.

31. The dosage form of claim 30, wherein the pregelatinized starch is present at an amount of about 31.25 mg.

32. The dosage form of claim 29, wherein the stearic acid is present at an amount of about 0.375 mg.

33. The dosage form of claim 29, wherein the lactose is anhydrous lactose.

34. The dosage form of claim 33, wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 125 mg.

35. The dosage form of claim 29, which is in the form of a standard size 3 or larger capsule.

36. The oral dosage form of claim 1, wherein the weight ratio of lactose to starch in the oral dosage form is from 2.25:1 to 3.75:1.

37. The oral dosage form of claim 1, which comprises: 1) Compound A, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount of 0.1 to 3 weight percent of the total weight of the dosage form; 2) a carrier or excipient at an amount of 90 to 99.5 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose, and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.1:1 to 3.9:1; and 3) a lubricant at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

38. The oral dosage form of claim 1, which comprises: 1) Compound A, or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount of 0.1 to 3 weight percent of the total weight of the dosage form; 2) a carrier or excipient at an amount of 90 to 99.5 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose, and wherein the weight ratio of lactose to starch in the oral dosage form is from 2.25:1 to 3.75:1; and 3) a lubricant at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.

39. The oral dosage form of claim 1, wherein the total weight of the oral dosage form is 150 mg.

40. The oral dosage form of claim 37, wherein the total weight of the oral dosage form is 150 mg.

41. The oral dosage form of claim 38, wherein the total weight of the oral dosage form is 150 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.